Though life-changing medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are only approved right now for type 2 diabetes, a growing body of evidence shows the potential benefits for people living with type 1 diabetes as well. Promising results from a new study on tirzepatide for people with type 1 diabetes were presented recently at the ATTD 2025 conference in Amsterdam. During the study, 84 adults with type 1 diabetes and overweight or obesity were given tirzepatide off-label. After 21 months, participants experienced 23% weight loss and sustained improvements in glucose management.